MedTrace Logo

Radiation Therapy in Patients With Limited-Stage Small Cell Lung Cancer in Complete Remission

NCT00005062 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2014-03-13

No results posted yet for this study

Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells and prevent the spread of cancer to the brain. It is not yet known if standard-dose radiation therapy is more effective than high-dose radiation therapy in preventing the spread of limited-stage small cell lung cancer cells to the brain.

PURPOSE: This randomized phase III trial is comparing two different regimens of radiation therapy to see how well they work in treating patients with limited-stage small cell lung cancer in complete remission.

Conditions

Interventions

RADIATION

radiation therapy

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    collaborator NETWORK

  • Gustave Roussy, Cancer Campus, Grand Paris

    lead OTHER

Principal Investigators

  • Cecile Le Pechoux, MD · Gustave Roussy, Cancer Campus, Grand Paris

  • Suresh Senan · Free University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-09-30
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • United States
  • Australia
  • Belgium
  • Brazil
  • Chile
  • China
  • Colombia
  • Cyprus
  • Czechia
  • France
  • Germany
  • Greece
  • Israel
  • Italy
  • Japan
  • Lithuania
  • Netherlands
  • North Macedonia
  • Poland
  • Portugal
  • Romania
  • Serbia
  • South Africa
  • South Korea
  • Spain
  • Switzerland
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00005062 on ClinicalTrials.gov